{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:27:33Z","timestamp":1789388853568,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T00:00:00Z","timestamp":1200009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The efficacy and safety of chemotherapy with irinotecan plus docetaxel were retrospectively evaluated for olfactory neuroblastoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twelve patients with histologically proven advanced or metastatic olfactory neuroblastoma were treated with chemotherapy with irinotecan plus docetaxel at the study institution between 2001 and 2005. Of these, 7 patients with locoregional disease and no prior radiotherapy received irinotecan plus docetaxel followed by definitive radiotherapy, 1 with photon radiotherapy and 6 with proton radiotherapy, whereas 3 patients with distant metastases and 2 with locoregional disease who had received prior radiotherapy received irinotecan plus docetaxel only.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The most common toxicities of \u2265grade 3 among the 12 patients receiving irinotecan plus docetaxel were leukopenia (33%), neutropenia (50%), febrile neutropenia (8%), and diarrhea (25%), all of which were manageable. Partial response was achieved in 3 patients, giving an overall response rate of 25%. The response rate was higher in patients aged &lt;50 years (3 of 4 patients) compared with those aged &gt;50 years (0 of 8 patients) (<jats:italic>P<\/jats:italic> = .018). With a median follow\u2010up period of 22.2 months, the median progression\u2010free survival and overall survival were 13.6 months and 36.6 months, respectively. Of the 7 patients with locoregional disease also receiving definitive radiotherapy, the 2\u2010year survival rate was 100% and 6 patients were alive at the time of last follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Chemotherapy for olfactory neuroblastoma with irinotecan plus docetaxel is safe and manageable. Patients aged &lt;50 years may be sensitive to chemotherapy. Induction chemotherapy followed by definitive radiotherapy may represent a promising option for patients with locally advanced olfactory neuroblastoma. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23246","type":"journal-article","created":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T16:51:56Z","timestamp":1200070316000},"page":"885-891","source":"Crossref","is-referenced-by-count":34,"title":["Nonplatinum\u2010based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma"],"prefix":"10.1002","volume":"112","author":[{"given":"Naomi","family":"Kiyota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197909)44:3<1087::AID-CNCR2820440343>3.0.CO;2-A"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1955.02950210014004"},{"key":"e_1_2_5_5_2","first-page":"410","article-title":"L'esthesioneroepitheliome olfactif","volume":"13","author":"Berger L","year":"1924","journal-title":"Bull Assoc Franc Etude Cancer."},{"key":"e_1_2_5_6_2","first-page":"2683","article-title":"Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924","volume":"17","author":"Broich G","year":"1997","journal-title":"Anticancer Res"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(88)90298-2"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(01)00558-7"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1058907"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90457-7"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2880150303"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20127"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1997.01900010038005"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10537"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-199910000-00001"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200008000-00007"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200103000-00020"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199805000-00040"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1042-3680(18)30094-9"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199004000-00010"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840301)53:5<1036::AID-CNCR2820530504>3.0.CO;2-3"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418600430833"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2006.00064.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.12.071"},{"key":"e_1_2_5_26_2","first-page":"938","article-title":"Phase I and pharmacokinetic study of weekly docetaxel (DOC) plus irinotecan (IRN) in patients with advanced solid tumors","volume":"46","author":"Kawada K","year":"2005","journal-title":"Proc Amer Assoc Cancer Res."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821201)50:11<2388::AID-CNCR2820501126>3.0.CO;2-K"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198505000-00001"},{"key":"e_1_2_5_29_2","series-title":"Tumors of the Upper Respiratory Tract and Ear","author":"Hyams V","year":"1988"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199305000-00002"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199011000-00013"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199208000-00001"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199805000-00045"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.1107"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20648"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20471"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2880160613"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1992.01880090029010"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23246","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:50:06Z","timestamp":1760305806000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23246"}},"subtitle":["A retrospective analysis of 12 cases"],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,2,15]]}},"alternative-id":["10.1002\/cncr.23246"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23246","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}